Differential Effects on Light Chain Amyloid Formation Depend on Mutations and Type of Glycosaminoglycans*

Background: Extracellular amyloid deposits involve glycosaminoglycans (GAGs). Results: Fibrillation of AL proteins was accelerated by heparan sulfate and inhibited by chondroitin sulfate A. Conclusion: Endogenous GAGs can modulate amyloid formation, and their effect is determined by the amyloidogenic properties of AL proteins studied. Significance: Biologically relevant molecules like GAGs play a major role in the amyloidogenicity of AL proteins. Amyloid light chain (AL) amyloidosis is a protein misfolding disease where immunoglobulin light chains sample partially folded states that lead to misfolding and amyloid formation, resulting in organ dysfunction and death. In vivo, amyloid deposits are found in the extracellular space and involve a variety of accessory molecules, such as glycosaminoglycans, one of the main components of the extracellular matrix. Glycosaminoglycans are a group of negatively charged heteropolysaccharides composed of repeating disaccharide units. In this study, we investigated the effect of glycosaminoglycans on the kinetics of amyloid fibril formation of three AL cardiac amyloidosis light chains. These proteins have similar thermodynamic stability but exhibit different kinetics of fibril formation. We also studied single restorative and reciprocal mutants and wild type germ line control protein. We found that the type of glycosaminoglycan has a different effect on the kinetics of fibril formation, and this effect seems to be associated with the natural propensity of each AL protein to form fibrils. Heparan sulfate accelerated AL-12, AL-09, κI Y87H, and AL-103 H92D fibril formation; delayed fibril formation for AL-103; and did not promote any fibril formation for AL-12 R65S, AL-103 delP95aIns, or κI O18/O8. Chondroitin sulfate A, on the other hand, showed a strong fibril formation inhibition for all proteins. We propose that heparan sulfate facilitates the formation of transient amyloidogenic conformations of AL light chains, thereby promoting amyloid formation, whereas chondroitin sulfate A kinetically traps partially unfolded intermediates, and further fibril elongation into fibrils is inhibited, resulting in formation/accumulation of oligomeric/protofibrillar aggregates.

[1]  R. Linhardt,et al.  Divergent effect of glycosaminoglycans on the in vitro aggregation of serum amyloid A. , 2014, Biochimie.

[2]  R. Kayed,et al.  Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. , 2014, Biochemical pharmacology.

[3]  M. Ramirez-Alvarado,et al.  Kinetic control in protein folding for light chain amyloidosis and the differential effects of somatic mutations. , 2014, Journal of molecular biology.

[4]  Marina Ramirez-Alvarado,et al.  Thermal Stability Threshold for Amyloid Formation in Light Chain Amyloidosis , 2013, International journal of molecular sciences.

[5]  J. Buxbaum,et al.  A molecular history of the amyloidoses. , 2012, Journal of molecular biology.

[6]  A. Dispenzieri,et al.  What do I need to know about immunoglobulin light chain (AL) amyloidosis? , 2012, Blood reviews.

[7]  B. Volkman,et al.  Tyrosine Residues Mediate Fibril Formation in a Dynamic Light Chain Dimer Interface , 2012, The Journal of Biological Chemistry.

[8]  Jonathan A. Fauerbach,et al.  Supramolecular non-amyloid intermediates in the early stages of α-synuclein aggregation. , 2012, Biophysical journal.

[9]  M. Ramirez-Alvarado,et al.  Glycosaminoglycans promote fibril formation by amyloidogenic immunoglobulin light chains through a transient interaction. , 2011, Biophysical chemistry.

[10]  A. Dispenzieri,et al.  Changes in serum‐free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis , 2011, American journal of hematology.

[11]  V. Trinkaus-Randall,et al.  Role of Glycosaminoglycan Sulfation in the Formation of Immunoglobulin Light Chain Amyloid Oligomers and Fibrils* , 2010, The Journal of Biological Chemistry.

[12]  M. Ramirez-Alvarado,et al.  Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains , 2010, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[13]  B. Nordén,et al.  Excited-State Properties of the Indole Chromophore. Electronic Transition Moment Directions from Linear Dichroism Measurements: Effect of Methyl and Methoxy Substituents , 2010 .

[14]  P. Dubin,et al.  Glycosaminoglycans as polyelectrolytes. , 2010, Advances in colloid and interface science.

[15]  B. Volkman,et al.  A single mutation promotes amyloidogenicity through a highly promiscuous dimer interface. , 2010, Structure.

[16]  Baltazar Becerril,et al.  A single mutation at the sheet switch region results in conformational changes favoring lambda6 light-chain fibrillogenesis. , 2010, Journal of molecular biology.

[17]  M. Ramirez-Alvarado,et al.  Structural alterations within native amyloidogenic immunoglobulin light chains. , 2009, Journal of molecular biology.

[18]  Joseph Zaia,et al.  Organ-specific Heparan Sulfate Structural Phenotypes* , 2009, Journal of Biological Chemistry.

[19]  D. A. Fernández‐Velasco,et al.  Thermodynamic and kinetic characterization of a germ line human lambda6 light-chain protein: the relation between unfolding and fibrillogenesis. , 2009, Journal of molecular biology.

[20]  M. Ramirez-Alvarado,et al.  Structural Insights into the Role of Mutations in Amyloidogenesis* , 2008, Journal of Biological Chemistry.

[21]  V. Uversky,et al.  Effect of methionine oxidation on the structural properties, conformational stability, and aggregation of immunoglobulin light chain LEN. , 2008, Biochemistry.

[22]  B. Volkman,et al.  Altered Dimer Interface Decreases Stability in an Amyloidogenic Protein* , 2008, Journal of Biological Chemistry.

[23]  M. Ramirez-Alvarado,et al.  Salts enhance both protein stability and amyloid formation of an immunoglobulin light chain. , 2008, Biophysical chemistry.

[24]  Jeffrey D. Esko,et al.  Heparan sulphate proteoglycans fine-tune mammalian physiology , 2007, Nature.

[25]  G. Merlini,et al.  Dangerous small B-cell clones. , 2006, Blood.

[26]  A. Varki Nothing in Glycobiology Makes Sense, except in the Light of Evolution , 2006, Cell.

[27]  M. Ramirez-Alvarado,et al.  The effects of sodium sulfate, glycosaminoglycans, and Congo red on the structure, stability, and amyloid formation of an immunoglobulin light‐chain protein , 2006, Protein science : a publication of the Protein Society.

[28]  R. Falk Diagnosis and Management of the Cardiac Amyloidoses , 2005, Circulation.

[29]  P. Adams,et al.  Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four Vλ6 proteins , 2004, Journal of molecular recognition : JMR.

[30]  Ivan Stamenkovic,et al.  Functional structure and composition of the extracellular matrix , 2003, The Journal of pathology.

[31]  V. Uversky,et al.  Structural transformations of oligomeric intermediates in the fibrillation of the immunoglobulin light chain LEN. , 2003, Biochemistry.

[32]  R. Fonseca,et al.  Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). , 2003, Blood.

[33]  M. Schiffer,et al.  Factors contributing to decreased protein stability when aspartic acid residues are in β‐sheet regions , 2002, Protein science : a publication of the Protein Society.

[34]  V. Uversky,et al.  Effect of Association State and Conformational Stability on the Kinetics of Immunoglobulin Light Chain Amyloid Fibril Formation at Physiological pH* , 2002, The Journal of Biological Chemistry.

[35]  V. Uversky,et al.  Elucidation of the Molecular Mechanism during the Early Events in Immunoglobulin Light Chain Amyloid Fibrillation , 2002, The Journal of Biological Chemistry.

[36]  Charles A. Janeway,et al.  INAUGURAL ARTICLE by a Recently Elected Academy Member:How the immune system works to protect the host from infection: A personal view , 2001 .

[37]  C. Ionescu-Zanetti,et al.  Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates. , 2001, Biochemistry.

[38]  F. Stevens,et al.  Immunoglobulin light chains, glycosaminoglycans, and amyloid , 2000, Cellular and Molecular Life Sciences CMLS.

[39]  M. Schell,et al.  Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity. , 1999, Biochemistry.

[40]  M C Manning,et al.  Tyrosine, phenylalanine, and disulfide contributions to the circular dichroism of proteins: circular dichroism spectra of wild-type and mutant bovine pancreatic trypsin inhibitor. , 1999, Biochemistry.

[41]  R. Falk,et al.  The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. , 1998, QJM : monthly journal of the Association of Physicians.

[42]  F. Stevens,et al.  Interaction between glycosaminoglycans and immunoglobulin light chains. , 1997, Biochemistry.

[43]  N. Schormann,et al.  Tertiary structure of an amyloid immunoglobulin light chain protein: a proposed model for amyloid fibril formation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Hurle,et al.  A role for destabilizing amino acid replacements in light-chain amyloidosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Pepys,et al.  Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils. , 1991, The Biochemical journal.

[46]  V. Trinkaus-Randall,et al.  Cellular response of cardiac fibroblasts to amyloidogenic light chains. , 2005, The American journal of pathology.

[47]  J. Buxbaum,et al.  The systemic amyloidoses. , 1998, The New England journal of medicine.

[48]  R. Wetzel Domain stability in immunoglobulin light chain deposition disorders. , 1997, Advances in protein chemistry.

[49]  R. Kyle,et al.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases. , 1995, Seminars in hematology.

[50]  M. Skinner,et al.  Glycosaminoglycans of the hemodialysis-associated carpal synovial amyloid and of amyloid-rich tissues and fibrils of heart, liver, and spleen. , 1990, Clinical chemistry.